You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

BRETHINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Brethine, and what generic alternatives are available?

Brethine is a drug marketed by Pharmacare and Ani Pharms and is included in two NDAs.

The generic ingredient in BRETHINE is terbutaline sulfate. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the terbutaline sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Brethine

A generic version of BRETHINE was approved as terbutaline sulfate by IMPAX LABS on June 26th, 2001.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BRETHINE?
  • What are the global sales for BRETHINE?
  • What is Average Wholesale Price for BRETHINE?
Drug patent expirations by year for BRETHINE
Recent Clinical Trials for BRETHINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yaakov BeilinPhase 2/Phase 3
Jaeb Center for Health ResearchPhase 1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 1

See all BRETHINE clinical trials

US Patents and Regulatory Information for BRETHINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacare BRETHINE terbutaline sulfate INJECTABLE;INJECTION 018571-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms BRETHINE terbutaline sulfate TABLET;ORAL 017849-001 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms BRETHINE terbutaline sulfate TABLET;ORAL 017849-002 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BRETHINE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacare BRETHINE terbutaline sulfate INJECTABLE;INJECTION 018571-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Ani Pharms BRETHINE terbutaline sulfate TABLET;ORAL 017849-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Ani Pharms BRETHINE terbutaline sulfate TABLET;ORAL 017849-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Ani Pharms BRETHINE terbutaline sulfate TABLET;ORAL 017849-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Ani Pharms BRETHINE terbutaline sulfate TABLET;ORAL 017849-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Pharmacare BRETHINE terbutaline sulfate INJECTABLE;INJECTION 018571-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BRETHINE

See the table below for patents covering BRETHINE around the world.

Country Patent Number Title Estimated Expiration
Germany 1643296 ⤷  Sign Up
Norway 132866 ⤷  Sign Up
Norway 124723 ⤷  Sign Up
Switzerland 512428 Verfahren zur Herstellung von neuen 1-(3',5'-Dihydroxy- bzw. -acyloxy-phenyl)-2-aminoäthanolen und deren physiologisch verträglichen Säureadditionssalzen ⤷  Sign Up
Switzerland 510625 Verfahren zur Herstellung von neuen 1-(3',5'-Dihydroxy- bzw. -acyloxy-phenyl)-2-aminoäthanolen und deren physiologisch verträglichen Säureadditionssalzen (1-3 5-dihydroxyphenyl-2-alkylaminoethanols) ⤷  Sign Up
Switzerland 510627 Verfahren zur Herstellung von neuen 1-(3',5'-Dihydroxy- bzw. -acyloxyphenyl)-2-cyclobutylaminoäthanolen und deren physiologisch verträglichen Säureadditionssalzen ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.